Compare PMTS & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | RANI |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.4M | 126.8M |
| IPO Year | 2015 | 2021 |
| Metric | PMTS | RANI |
|---|---|---|
| Price | $17.42 | $0.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $27.67 | $7.50 |
| AVG Volume (30 Days) | 36.7K | ★ 980.1K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.14 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $312,189,000.00 | $1,633,000.00 |
| Revenue This Year | $9.95 | $274.77 |
| Revenue Next Year | $10.02 | $79.44 |
| P/E Ratio | $14.67 | ★ N/A |
| Revenue Growth | 12.27 | ★ 58.85 |
| 52 Week Low | $10.81 | $0.39 |
| 52 Week High | $27.31 | $3.87 |
| Indicator | PMTS | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 41.83 |
| Support Level | $13.01 | $0.45 |
| Resistance Level | $18.09 | $1.05 |
| Average True Range (ATR) | 1.04 | 0.08 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 16.72 | 46.98 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.